CIPDD SBMS

[CIPDD SBMS @cipdd_sbms]

J-2156 .... alleviated hindpaw hypersensitivity in the streptozotocin-induced rat model of painful diabetic neuropathy but with a 2-fold decrease in potency at an advanced stage in the model, mimicking morphine

https://t.co/P9woZarT1W

@MareeSmith19

[CIPDD SBMS @cipdd_sbms]

Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation

Andrew J. Shepherd, Andrew SC. Rice, Maree T. Smith

https://t.co/YLQ5h97Ivm @MareeSmith19

[CIPDD SBMS @cipdd_sbms]

In Vitro Assessment of the Metabolic Stability of Two Novel Endomorphin-2 Analogs, CYX-5 and CYX-6, in Rat Liver Microsomes

https://t.co/cBwKC27vSg @MareeSmith19

[CIPDD SBMS @cipdd_sbms]

The NLRP3 inflammasome: role in the pathobiology of chronic pain

https://t.co/HElFPNX0sJ @MareeSmith19

[CIPDD SBMS @cipdd_sbms]

Multitargeted Opioid Ligand Discovery as a Strategy to Retain Analgesia and Reduce Opioid-Related Adverse Effects https://t.co/3J7feMYxYF @MareeSmith19

[CIPDD SBMS @cipdd_sbms]

Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources https://t.co/RdcWx7fx1s @MareeSmith19

[CIPDD SBMS @cipdd_sbms]

The full-text of "Assessment of the anti‑allodynic efficacy of a glycine transporter 2 inhibitor relative to pregabalin and duloxetine in a rat model of prostate cancer‑induced bone pain" is now accessible. https://t.co/sK457bpVyv

[CIPDD SBMS @cipdd_sbms]

Evaluation of a GlyT2 inhibitor c.f. pregabalin & duloxetine for relief of prostate cancer-induced bone pain in rats. https://t.co/8BHOqDVs5F